
Sep 23, 2026
Altimmune to Participate in Stifel Cardiometabolic Forum
Altimmune, Inc. announced its management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026, at 10:30 a.m. ET. The company, a late clinical-stage biopharmaceutical firm, is developing pemvidutide for serious liver diseases, including MASH, AUD, and ALD. A webcast of the chat will be available on Altimmune's website.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral